Front Oncol 2021 21;11:644854. Epub 2021 Apr 21.
Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Fibroblast growth factor receptor 2 (FGFR2) is frequently altered in tumors and one of the top therapeutic targets in cholangiocarcinoma (CHOL) with fusions. Although there have been several studies on individual tumors, a comprehensive analysis of genetic aberrations and their simultaneous clinical implications across different tumors have not been reported. In this study, we used the large comprehensive datasets available, covering over 10,000 tumor samples across more than 30 cancer types, to analyze abnormal expression, methylation, alteration (mutations/fusions and amplification/deletion), and their clinical associations. Read More